iSelect Fund — 2015 Investments

2 investments dated 2015 · listed companies and verified rows first · show all

Evolve Biosystemsevolvebiosystems.com in 𝕏Jul 2015

Evolve Biosystems develops probiotic strains of B. infantis, including EVC001 and a next-generation drug strain INF108, aimed at supporting the infant gut microbiome and preventing necrotizing enterocolitis (NEC) in premature infants.

BiotechHealthtechMedical DevicesDavis, US

J. Bruce German(Director)David Mills(Executive Officer)David J. Kyle(Executive Officer, Director)John Campbell(Executive Officer)James Campbell(Executive Officer)

BoardDaniel Janney(Director)

Co-investorsSpruce Capital Partners

SciBac, Inc.scibac.comJul 2015

BiotechSunnyvale, US

Lawrence Wade Fry(Executive Officer, Director, Promoter)Jeanette Marie Mucha(Executive Officer, Director, Promoter)Anthony Cann Cann(Executive Officer, Director, Promoter)Derik Anthony Twomey(Director, Promoter)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.